The increasing role of monoamine oxidase type B inhibitors in Parkinson's disease therapy

Lawrence W. Elmer, John M. Bertoni

Research output: Contribution to journalReview article

32 Citations (Scopus)

Abstract

Background: The role of monoamine oxidase type B inhibitors in the treatment of Parkinson's disease has expanded with the new monoamine oxidase B inhibitor rasagiline and a new formulation, selegiline oral disintegrating tablets. As primary therapy in early disease monoamine oxidase B inhibitors reduce motor disability and delay the need for levodopa. In more advanced disease requiring levodopa, adjunctive monoamine oxidase B inhibitors reduce 'off' time and may improve gait and freezing. Objective: Rasagiline and selegiline oral disintegrating tablets may reduce the safety risks associated with the amfetamine and methamfetamine metabolites of conventional oral selegiline while retaining or improving therapeutic efficacy. Methods: Articles were identified by searches of PubMed and searches on the Internet and reviewed. All articles and other referenced materials were retrieved using the keywords 'Parkinson's disease', 'treatment' and 'monoamine oxidase B inhibitor' and were published between 1960 and 2007, with older references selected for historical significance. Only papers published in English were reviewed. Conclusion: Accumulating data support the use of monoamine oxidase B inhibitors as monotherapy for early and mild Parkinson's disease and as adjunctive therapy for more advanced Parkinson's disease with levodopa-associated motor fluctuations. The recently released monoamine oxidase B inhibitor rasagiline and a new formulation, selegiline oral disintegrating tablets, have potential advantages over conventional oral selegiline.

Original languageEnglish (US)
Pages (from-to)2759-2772
Number of pages14
JournalExpert Opinion on Pharmacotherapy
Volume9
Issue number16
DOIs
StatePublished - Nov 1 2008

Fingerprint

Monoamine Oxidase Inhibitors
Monoamine Oxidase
Selegiline
Parkinson Disease
Levodopa
Tablets
Therapeutics
Amphetamine
Gait
PubMed
Internet
Freezing
Safety
rasagiline

Keywords

  • Levodopa
  • Monoamine oxidase inhibitor
  • Parkinson's disease
  • Selegiline

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

The increasing role of monoamine oxidase type B inhibitors in Parkinson's disease therapy. / Elmer, Lawrence W.; Bertoni, John M.

In: Expert Opinion on Pharmacotherapy, Vol. 9, No. 16, 01.11.2008, p. 2759-2772.

Research output: Contribution to journalReview article

@article{ff3bb14cf1a7462e8f81865bb1c97eca,
title = "The increasing role of monoamine oxidase type B inhibitors in Parkinson's disease therapy",
abstract = "Background: The role of monoamine oxidase type B inhibitors in the treatment of Parkinson's disease has expanded with the new monoamine oxidase B inhibitor rasagiline and a new formulation, selegiline oral disintegrating tablets. As primary therapy in early disease monoamine oxidase B inhibitors reduce motor disability and delay the need for levodopa. In more advanced disease requiring levodopa, adjunctive monoamine oxidase B inhibitors reduce 'off' time and may improve gait and freezing. Objective: Rasagiline and selegiline oral disintegrating tablets may reduce the safety risks associated with the amfetamine and methamfetamine metabolites of conventional oral selegiline while retaining or improving therapeutic efficacy. Methods: Articles were identified by searches of PubMed and searches on the Internet and reviewed. All articles and other referenced materials were retrieved using the keywords 'Parkinson's disease', 'treatment' and 'monoamine oxidase B inhibitor' and were published between 1960 and 2007, with older references selected for historical significance. Only papers published in English were reviewed. Conclusion: Accumulating data support the use of monoamine oxidase B inhibitors as monotherapy for early and mild Parkinson's disease and as adjunctive therapy for more advanced Parkinson's disease with levodopa-associated motor fluctuations. The recently released monoamine oxidase B inhibitor rasagiline and a new formulation, selegiline oral disintegrating tablets, have potential advantages over conventional oral selegiline.",
keywords = "Levodopa, Monoamine oxidase inhibitor, Parkinson's disease, Selegiline",
author = "Elmer, {Lawrence W.} and Bertoni, {John M.}",
year = "2008",
month = "11",
day = "1",
doi = "10.1517/14656566.9.16.2759",
language = "English (US)",
volume = "9",
pages = "2759--2772",
journal = "Expert Opinion on Pharmacotherapy",
issn = "1465-6566",
publisher = "Informa Healthcare",
number = "16",

}

TY - JOUR

T1 - The increasing role of monoamine oxidase type B inhibitors in Parkinson's disease therapy

AU - Elmer, Lawrence W.

AU - Bertoni, John M.

PY - 2008/11/1

Y1 - 2008/11/1

N2 - Background: The role of monoamine oxidase type B inhibitors in the treatment of Parkinson's disease has expanded with the new monoamine oxidase B inhibitor rasagiline and a new formulation, selegiline oral disintegrating tablets. As primary therapy in early disease monoamine oxidase B inhibitors reduce motor disability and delay the need for levodopa. In more advanced disease requiring levodopa, adjunctive monoamine oxidase B inhibitors reduce 'off' time and may improve gait and freezing. Objective: Rasagiline and selegiline oral disintegrating tablets may reduce the safety risks associated with the amfetamine and methamfetamine metabolites of conventional oral selegiline while retaining or improving therapeutic efficacy. Methods: Articles were identified by searches of PubMed and searches on the Internet and reviewed. All articles and other referenced materials were retrieved using the keywords 'Parkinson's disease', 'treatment' and 'monoamine oxidase B inhibitor' and were published between 1960 and 2007, with older references selected for historical significance. Only papers published in English were reviewed. Conclusion: Accumulating data support the use of monoamine oxidase B inhibitors as monotherapy for early and mild Parkinson's disease and as adjunctive therapy for more advanced Parkinson's disease with levodopa-associated motor fluctuations. The recently released monoamine oxidase B inhibitor rasagiline and a new formulation, selegiline oral disintegrating tablets, have potential advantages over conventional oral selegiline.

AB - Background: The role of monoamine oxidase type B inhibitors in the treatment of Parkinson's disease has expanded with the new monoamine oxidase B inhibitor rasagiline and a new formulation, selegiline oral disintegrating tablets. As primary therapy in early disease monoamine oxidase B inhibitors reduce motor disability and delay the need for levodopa. In more advanced disease requiring levodopa, adjunctive monoamine oxidase B inhibitors reduce 'off' time and may improve gait and freezing. Objective: Rasagiline and selegiline oral disintegrating tablets may reduce the safety risks associated with the amfetamine and methamfetamine metabolites of conventional oral selegiline while retaining or improving therapeutic efficacy. Methods: Articles were identified by searches of PubMed and searches on the Internet and reviewed. All articles and other referenced materials were retrieved using the keywords 'Parkinson's disease', 'treatment' and 'monoamine oxidase B inhibitor' and were published between 1960 and 2007, with older references selected for historical significance. Only papers published in English were reviewed. Conclusion: Accumulating data support the use of monoamine oxidase B inhibitors as monotherapy for early and mild Parkinson's disease and as adjunctive therapy for more advanced Parkinson's disease with levodopa-associated motor fluctuations. The recently released monoamine oxidase B inhibitor rasagiline and a new formulation, selegiline oral disintegrating tablets, have potential advantages over conventional oral selegiline.

KW - Levodopa

KW - Monoamine oxidase inhibitor

KW - Parkinson's disease

KW - Selegiline

UR - http://www.scopus.com/inward/record.url?scp=56749085833&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=56749085833&partnerID=8YFLogxK

U2 - 10.1517/14656566.9.16.2759

DO - 10.1517/14656566.9.16.2759

M3 - Review article

C2 - 18937611

AN - SCOPUS:56749085833

VL - 9

SP - 2759

EP - 2772

JO - Expert Opinion on Pharmacotherapy

JF - Expert Opinion on Pharmacotherapy

SN - 1465-6566

IS - 16

ER -